Compare FNWD & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FNWD | ALGS |
|---|---|---|
| Founded | 1994 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 164.2M | 39.9M |
| IPO Year | 1996 | 2020 |
| Metric | FNWD | ALGS |
|---|---|---|
| Price | $34.07 | $5.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $37.50 | ★ $39.33 |
| AVG Volume (30 Days) | 5.9K | ★ 126.9K |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.51% | N/A |
| EPS Growth | N/A | ★ 88.30 |
| EPS | ★ 0.52 | N/A |
| Revenue | N/A | ★ $2,186,000.00 |
| Revenue This Year | $17.40 | $32.20 |
| Revenue Next Year | $5.44 | $4.71 |
| P/E Ratio | $65.53 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $26.46 | $5.12 |
| 52 Week High | $39.99 | $13.69 |
| Indicator | FNWD | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 45.08 | 42.93 |
| Support Level | $30.99 | N/A |
| Resistance Level | $33.04 | $6.82 |
| Average True Range (ATR) | 1.01 | 0.51 |
| MACD | 0.28 | -0.04 |
| Stochastic Oscillator | 44.57 | 36.15 |
Finward Bancorp is a bank holding company, which engages in the provision of financial services. It offers products and services related to Personal Banking, Cash Management, Saving Account, ebanking, Wealth Management, and Insurance Services. It is engaged in the business of attracting deposits from the general public and the origination of loans, mostly upon the security of single-family residences and commercial real estate, construction loans, commercial business loans, and municipal loans. Geographically, the activities are carried out through the United States.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.